C&L: Fiorini new chairman at Egalet

Egalet has asked Michael Fiorini to step in as the company's new chairman. Fiorini replaces Egalet's existing chairman, Seppo Mäkinen. Egalet has also appointed Peter Nordkild, formerly chief commercial officer of Pharmexa, as CEO.

Nitec Pharma AG has appointed Anders Harfstrand as Chief Executive Officer, and Andrea Buscaglia as Chief Financial Officer.

Takeda San Diego announced that Keith Wilson, Ph.D. has been named president and chief scientific officer.

Danish drugmaker Novo Nordisk AS has hired Jerzy Gruhn as president of its U.S. affiliate, Novo Nordisk Inc., and senior vice president of Novo Nordisk North America.

Prestwick Pharmaceuticals has hired Martin Stogniew, Ph.D. as executive vice president, chief technology officer. 

Emisphere Technologies has appointed Michael R. Garone to the position of chief financial officer.

Auriga Laboratories has appointed Frank R. Greico as its chief financial officer. 

Magellan Biosciences has hired Steven E. Diamond, PhD, as chief scientific officer.  

Cubist Pharmaceuticals has named Rob Perez as executive vice president and chief operating officer.

Quark Pharmaceuticals has appointed J. Joseph Marr, M.D., as the company's new chief medical officer. 

Benda Pharmaceutical has appointed Jinghai Xu as general manager of the Benda Ebei plant. 

Neurogen Corporation has named George D. Maynard, Ph.D. to the position of vice president, early development.

Novacea announced that James Blair, Ph.D., of Domain Associates and Jay Moorin of ProQuest Investments will resign as members of the board of directors in September 2007.

Osiris Therapeutics announced the formation of a Nuclear and Radiological Countermeasure Advisory Board: Steven Bice, Martin Hauer-Jensen, M.D., Ph.D., Hans Klingemann, M.D., Ph.D., Thomas J. MacVittie, Ph.D., and Major General John S. Parker, M.D. US Army (Ret.)

Nektar Therapeutics has named Lutz Lingnau to its board of directors.

EyeGate Pharma has named Paul G. Chaney as a member of the board of directors.

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.